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Abstract 
Drug hypersensitivity reactions (DHRs) affect an unknown proportion of the general population, and are an important 
public health problem due to their potential to cause life-threatening anaphylaxis and rare severe cutaneous aller-
gic reactions. DHR evaluations are frequently needed in both ambulatory and hospital settings and have a complex 
diagnosis that requires a detailed clinical history and other tests that may include in vitro tests and in vivo procedures 
such as skin tests and drug provocation tests. Although over the years both European and U.S. experts have published 
statements on general procedures for evaluating DHRs, a substantial discordance in their daily management exists. In 
this review, we highlight both the differences and the similarities between the European and U.S. perspectives. While 
a general consensus exists on the importance of skin tests for evaluating DHRs, concordance between Americans and 
Europeans exists solely regarding their use in immediate reactions and the fact that a confirmation of a presumptive 
diagnosis by drug provocation tests is often the only reliable way to establish a diagnosis. Finally, great heterogeneity 
exists in the application of in vitro tests, which require further study to be well validated.
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Background
Drugs can induce immunologically mediated adverse 
reactions that, together with non-allergic direct mast-cell 
mediated drug hypersensitivity reactions (DHRs), com-
prise 15% of all adverse drug reactions [1]. Only when a 
definite immunological mechanism (either clinically sig-
nificant drug-specific IgE or IgG antibodies or T cells) 
is demonstrated, these reactions should be classified as 
drug allergic reactions [2].
DHRs are commonly classified as immediate (IDHR) 
or non-immediate (NIDHR) depending on their onset 
during treatment [3]. IDHRs are mainly induced by an 
IgE- or IgG and complement-mediated mechanism and 
occur within 1–6  h after the last drug administration. 
NIDHRs occur at least 1 h after the initial drug admin-
istration in sensitized patients, but usually after sev-
eral hours or even days, and are often associated with a 
delayed IgG-mediated or T cell-dependent mechanism 
[4].
While clinically IDHRs can affect any organ system, 
the skin is the most frequently involved, with the most 
common manifestation being urticaria/angioedema and 
the most severe being anaphylaxis/anaphylactic shock. 
The most common clinical manifestations of NIDHR 
are benign rashes, especially urticaria and maculopapu-
lar eruptions. However, serious cutaneous adverse reac-
tions (SCAR)—such as, acute generalized exanthematous 
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Stevens–Johnson syndrome (SJS), and drug reaction with 
eosinophilia and systemic symptoms (DRESS) or drug-
induced hypersensitivity syndrome (DiHS)—can rarely 
occur [4].
Drug intolerances are reported in the medical records 
of about 8% of the populations that use modern health-
care, but only a small minority of them are indisputably 
immunologically mediated DHRs. Though DHRs affect an 
unknown proportion of the general population, they are an 
important public health problem because of their poten-
tial to cause life-threatening anaphylaxis and rare SCAR. 
Drug intolerance reports dramatically alter medications 
individuals are subsequently exposed to and can cause 
additional morbidity because of the consequences of sub-
optimal pharmacotherapy. DHR evaluations are a frequent 
demand in both ambulatory and hospital settings. DHRs 
can pose complex diagnostic problems requiring a detailed 
clinical history and other tests that may include in  vitro 
tests and in vivo procedures, such as skin tests (STs) and 
drug provocation tests (DPTs), also called graded chal-
lenges or test doses in the U.S. literature.
The reference standard for drug tolerance is no evi-
dence of reaction after a therapeutic dose of the impli-
cated drug. For a suspected IgE-mediated IDHR at least 
1–6 h of observation are necessary. For a suspected T-cell 
mediated NIDHR 5  days-several weeks of observation 
may be necessary. Diagnostic testing, which may include 
STs and in  vitro testing, is performed to minimize the 
number of serious positive DPTs. Over the years both 
European and U.S. experts have published statements on 
general procedures for evaluating DHRs [5–7]. However, 
there are still substantial differences in the daily manage-
ment of DHRs around the world.
In this review, the similarities and differences between 
European and U.S. perspectives of management of DHRs 
will be discussed.
Skin tests
In both the European [6, 8] and American [9] guidelines, 
STs are considered of paramount importance for evaluat-
ing DHRs. The European guidelines (EUgd) [6, 8] advise 
applying STs according to the suspected pathogenic 
mechanism of the DHRs. In IDHRs to β-lactams, for 
example, an IgE-mediated pathogenic mechanism can be 
demonstrated by a positive skin prick test (SPT) and/or 
intradermal test (IDT) after 20-min, whereas in NIDHRs, 
often a positive patch test (PT) and/or a late-reading IDT 
is found after several hours or days, indicating a T-cell-
mediated pathogenic mechanism.
The U.S. practice parameter (USpp) [9] highlights 
mainly the usefulness of STs for assessing IDHRs to 
drugs, such as benzylpenicillin, insulin, heterologous 
antisera, and streptokinase, for which optimal negative 
predictive values (NPV) for IgE-mediated reactions have 
been established. According to this parameter [9], a posi-
tive immediate-reading ST result using a non-irritating 
concentration of a drug suggests that the patient has 
drug-specific IgE (sIgE) and may be at significant risk for 
anaphylaxis or less severe IDHRs.
The manner in which NIDHRs are evaluated differs sig-
nificantly between the U.S. and Europe [10]. In European 
centres, patients with NIDHRs are evaluated by both PTs 
and delayed-reading IDTs [8], including those with severe 
NIDHRs, such as TEN/SJS, DRESS/DiHS, and AGEP 
[8, 11, 12]. PTs are usually performed first (i.e., prior to 
IDTs) and if positive, IDTs are avoided; if PTs are nega-
tive, in subjects with severe NIDHRs IDTs are performed 
using higher drug dilutions [8]. The clinical relevance of 
PTs or IDTs is not clear as, given the severity of these 
reactions, DPTs to confirm true allergy are not done.
In the U.S., PTs and delayed-reading IDTs are not rou-
tinely performed, probably because of limited data on 
test sensitivity combined with U.S. practice differences. 
For example, patients with SCAR may be diagnosed and 
managed by dermatologists who do not perform PTs or 
STs, with allergists only infrequently managing NIDHRs 
(i.e., when the clinical history and biopsy are not conclu-
sive). For benign maculopapular rashes and fixed drug 
eruption (FDE), a positive PT or IDT would not change 
management recommendations, and would therefore 
probably not be incorporated into U.S. clinical practice. 
The USpp on contact dermatitis [13] states that PT to 
drugs may have a role in some NIDHRs, such as macu-
lopapular rashes, AGEP, and FDE. This parameter gives 
a weak recommendation for PTs based on low quality 
evidence stating that: “there is no standardized approach 
to define the population, clinical manifestation, drug to 
PT, and PT materials to make PTs to drugs a standard of 
care”.
Recently, the European Network on Drug Allergy 
(ENDA) and European Academy of Allergy and Clinical 
Immunology (EAACI) Interest Group on Drug Allergy 
wrote a position paper on ST concentrations for system-
atically administered drugs [6]. However, it was possi-
ble to recommend specific drug concentrations only for 
β-lactam antibiotics, perioperative drugs, heparins, plati-
num salts, and iodinated contrast media (ICM). In effect, 
ST sensitivity appeared to be moderate to high for imme-




In both the EUgd [14, 15] and USpp [9], STs represent 
the first-line method for diagnosing IDHRs to β-lactams 
(Table 1). With regard to benzylpenicillin [9, 14, 15], STs 
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Table 1 Similarities and differences between Americans and Europeans in the management of β-lactam antibiotic hyper-
sensitivity
American perspective European perspective Comment
General rules Evaluation mainly by signs and symptoms
In history of severe reactionsa: avoidance of allergy tests
In history of non-severe reactions: diagnostic approach 
can be applied
Evaluation by clinical history and allergy tests Different
DPTs Recommended if other diagnostic tools are negative
Consider contraindications




Consider indications and contraindications
Recommended
Consider indications and contraindications
Similar
Immediate reactions
General rules SPTs followed by IDTs are the first to perform
Perform DPTs if STs are negative
SPTs followed by IDTs are the first to perform




PPL: 5 × 10−5 mol/L
MDM: 2 × 10−2 mol/L
BP: 10,000 IU/mL
Recommended
PPL: 5 × 10−5 mol/L









Not recommendeda Recommended with original drug and the individual compo-
nents of the antibiotic combination
Different
Cephalosporins




Imipenem/cilastatin: 0.5 mg/mL of each component;
Meropenem: 1 mg/mL; Ertapenem: 1 mg/mL
Different
Commercially available kits
PRE-PEN® (AllerQuest LLC, Plainville, CT, USA)
PPL: 6.0 × 10−5 mol/L
DAP® (Diater, Leganés, Madrid, Spain)
BP-OL: 0.04 mg/mL (8.64 × 10−5 mol/L)
MD: Benzylpenilloate 0.5 mg/mL (1.5 × 10−3 mol/L)
AX: 20 mg/mL
Different
In vitro tests Serum specific IgE assays
Not recommended Testing with penicillins is recommended Different
Basophil activation tests
Not recommended Recommended as complementary to sIgE Different
Non-immediate reactions
STs/PTs Not recommended PTs followed by delayed-reading IDTs are recommended in 
routine approach
In case of positive PTs, IDTs may be avoided
Different
In vitro tests Not recommended Not recommended Similar
Retest
Repeating penicillin STs routinely is not indicated in 
patients with a history of non-severe penicillin reactions 
who have tolerated 1 or more oral penicillin courses
Weakly recommended: retesting (2–4 weeks later) patients 
who suffered severe immediate reactions to BLs and 
display negative results in the first allergy evaluation, 
including DPTs
DPTs drug provocation tests, STs skin tests, SPTs skin prick tests, IDTs intradermal tests, PTs patch tests, PPL benzylpenicilloyl-poly-l-lysine, POL benzylpenicilloyl-octa-l-
lysine, MDM minor determinant mixture, MD minor determinant, BP Benzylpenicillin, AX amoxicillin, AMP ampicillin, sIgE specific IgE
a Due to unknown negative predictive values of STs
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should be performed with the classic benzylpenicillin 
reagents: benzylpenicilloyl-poly-l-lysine (PPL), minor 
determinant mixture (MDM: benzylpenicillin, benzylpe-
nilloate and benzylpenicilloate), and benzylpenicillin 
itself. In the US, the only minor determinant commer-
cially available is benzylpenicillin and thus most US aller-
gists do not routinely test with a complete MDM. The 
highest concentrations recommended in both SPTs and 
IDTs and the commercially available kits of penicillin 
reagents are shown in Table 1. It should be noted that, in 
the aforesaid European documents [6, 14, 15], the correct 
values of reagent concentrations expressed in mol/L were 
changed incorrectly to mmol/L.
According to the USpp [9], the NPV of STs with classic 
penicillin reagents approaches 100%, whereas the positive 
predictive value (PPV) is between 40 and 100%. STs with 
PPL and benzylpenicillin only (without benzylpenicilloate 
or benzylpenilloate) appear to have adequate NPV in the 
evaluation of benzylpenicillin allergy, but not amoxicillin 
or other β-lactam allergies. On the contrary, the NPV of 
STs without PPL is poor because many allergic patients 
show ST reactivity only to the major determinant.
As far as IDHRs to semisynthetic penicillins are con-
cerned, in Europe, amoxicillin, ampicillin, and other 
suspected semisynthetic penicillins for parenteral admin-
istration are recommended for STs at concentrations up 
to 20  mg/mL [6], in addition to PPL, MDM, and ben-
zylpenicillin. The final concentration of these penicillins, 
which are sodium salts, ranges from 100 to 200 mg/mL; 
thus it is easy to obtain a solution of 20 mg/mL. On the 
other hand, the USpp [9] states that: “The NPV of STs 
with native semisynthetic penicillins is unknown, and 
there is no consensus regarding the appropriate con-
centration that should be used”. In any case, in North 
America, while ampicillin is available, the trihydrate of 
amoxicillin has been used, which limits the concentra-
tion that can be prepared for STs to about 4 mg/mL [16, 
17]. In the U.S., an amoxicillin challenge following nega-
tive benzylpenicillin STs is routinely done, eliminating 
the need for aminopenicillin STs given the rarity of side-
chain specific reactions in the U.S.
When β-lactams are used in combination with a 
β-lactamase inhibitor (e.g., amoxicillin and clavulanic acid), 
the EUgd [6, 15] recommend STs with the original drug and 
individual components of the antibiotic combination.
For the investigation of IDHRs to cephalosporins, 
according to the EUgd [6, 14, 15], the suspected cepha-
losporin, PPL, MDM and β-lactams with similar side 
chains are used. The highest cephalosporin concentra-
tion recommended by the EUgd in both SPTs and IDTs is 
2 mg/mL [6]. However, taking into account some studies 
[12, 18], the EUgd also state that: “… for cefuroxime, cef-
triaxone, cefotaxime, ceftazidime, cefazolin, cephalexin, 
cefaclor, and cefatrizine, but not cefepime, concentra-
tions up to 20 mg/mL are probably also not irritant and 
might improve the sensitivity without affecting the speci-
ficity” [18]. On the other hand, the USpp [9] states that: 
“STs with native cephalosporins is not standardized, but 
a positive ST result using a non-irritating concentration 
suggests the presence of drug specific IgE antibodies. A 
negative ST result does not rule out an allergy because 
the NPV is unknown”.
With regard to aztreonam and carbapenems, the USpp 
[9] states that STs with a non-irritating concentration of 
native antibiotics have the same limitation and question-
able NPV as with cephalosporins.
Non‑immediate reactions
The EUgd [15, 19] recommend assessing NIDHRs to 
β-lactams by both PTs and delayed-reading IDTs. PTs with 
the suspected β-lactams are usually performed first; if posi-
tive, IDTs may be avoided. Delayed-reading IDTs generally 
have a higher sensitivity than PTs, with a similar specificity 
[20], and STs with PPL and MDM are scarcely useful [20]. 
PTs and delayed-reading IDTs are negative in most patients 
who experienced mild NIDHRs, particularly to cephalo-
sporins [21], and therefore, PTs may be avoided [22].
The most common approach in the U.S. is to diagnose 
NIDHRs to β-lactams based upon signs and symptoms 
[10]. In patients with severe reactions, β-lactams are sim-
ply avoided. If the NIDHRs involved hives or angioedema, 
the patient may be evaluated for IgE-mediated allergy 
to the β-lactam that caused the reaction, as well as the 
β-lactam that is needed in the immediate future. If the 
patient’s past reaction did not involve hives or angioedema 
and was mild (e.g., maculopapular rash), according to the 
USpp [9], penicillin STs should be considered before a 
future course of penicillin is given. In case of a negative 
result, DPTs to the desired β-lactam can be performed.
Non‑β‑lactam antibiotics
Both the USpp [9] and EUgd [6] agree that STs with non-
irritating concentrations of non-β-lactam antibiotics 
are not standardized. According to the latter document 
[6], for most non-β-lactam antibiotics, the value of STs 
appears to be uncertain and false-positive reactions may 
occur when the antibiotic is tested at high concentrations. 
The EUgd [6, 8] recommend studying NIDHRs to non-β-
lactam antibiotics by using PTs and delayed-reading IDTs.
Non‑steroidal anti‑inflammatory drugs (NSAIDs)
The USpp [9] and EUgd [6] agree that most IDHRs to 
NSAIDs (excluding pyrazolones) are not IgE-mediated 
but related to an aberrant arachidonic acid metabolism. 
Therefore, the EUgd recommend performing STs with 
pyrazolones although sensitivity is not optimal and risk 
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of systemic responses after IDTs exists [23]. In the U.S., 
pyrazolones are not available and NSAID STs are not rec-
ommended and rarely performed.
Considering non-pyrazolone single-NSAID-induced 
urticaria/angioedema or anaphylaxis (SNIUAA), STs with 
the culprit drug may be performed to confirm a selective, 
IgE-mediated type of hypersensitivity, although their use-
fulness has not been proven in large series [23]. In this 
regard, the EUgd [6] indicate that the irritating potential 
of all NSAIDs appears to be low in SPTs, and the specific-
ity is thus high (>95%); for IDTs, up to 0.1 mg/mL appear 
to not irritate the skin.
In NIDHRs [6, 23], PTs and delayed-reading IDTs show 
low sensitivity, but high specificity. Delayed-reading IDTs 
with NSAIDs, particularly metamizol, are more sensi-
tive than PTs. The latter tests with up to 10% or even 30% 
NSAID in petrolatum do not seem to irritate the skin, 
“although the additional value of using the higher con-
centration is questionable” [6].
Cancer chemotherapeutic agents
According to both the USpp [9] and EUgd [6], STs are 
useful for evaluating platinum salt-related IDHRs, while 
for other chemotherapeutic drugs (i.e., taxol) experience 
is limited and clinical usefulness not clear. For platinum 
salts (cisplatin, carboplatin, and oxaliplatin), the use of 
undiluted drugs is recommended by the American doc-
ument [9] for diagnosing hypersensitivity, identifying 
patients at risk, and determining the indication and pro-
tocol of desensitization [24].
The EUgd [6] state that the irritant potential of chem-
otherapeutic drugs is low and recommend SPTs with 
carboplatin at 10  mg/mL, oxaliplatin at 1  mg/mL, and 
cisplatin at 1 mg/mL, and IDTs at 1, 0.1 and 0.1 mg/mL, 
respectively. For other chemotherapeutic drugs, SPTs 
with undiluted agents are probably non-irritant, but due 
to toxicity concerns, a general recommendation cannot be 
given [6] and for IDTs, a 1/10 dilution may be used. IDTs 
with carboplatin at 10  mg/mL can cause skin necrosis 
and scarring and should be avoided [25]. PTs are almost 
always negative; thus, they are not recommended [6].
Perioperative agents
According to both the USpp [9] and EUgd [6], the evalu-
ation of hypersensitivity reactions to perioperative agents 
should include STs with all substances the patient was 
exposed to, including antibiotics, colloids, latex, dis-
infectants, opioids, blue dyes, etc. Recommended ST 
concentrations are shown in Table  2 [6, 26]. Both the 
American [9] and European documents [6] agree that 
neuromuscular blocking agents (NMBAs) and opiates 
can induce non-specific histamine release in the skin, 
increasing the possibility of false-positive tests, especially 
IDTs. The latter document [6] recommends performing 
IDTs with a panel of NMBAs, including the suspected 
one, in order to assess cross-reactivity and identify safe 
alternatives, and not carrying out routinely preoperative 
screening in patients without prior reactions.
The USpp on drug allergy [9] and the ones on the diag-
nosis and management of anaphylaxis [26, 27] highlight 
the usefulness of STs with thiopental, protamine, propo-
fol, and blue dyes (e.g., methylene blue, isosulfan blue, 
and patent blue V). Moreover, chlorhexidine is an inte-
gral part of the perioperative test panel in some European 
and U.S. centres [28, 29].
Finally, there are no recommendations for evaluat-
ing NIDHRs to perioperative drugs [6] except opiates, 
although there is no universal agreement on the optimal 
vehicle (aqua, petrolatum, ethanol) or test concentration.
Local anaesthetics
The USpp [9] and EUgd [6] agree that hypersensitivity 
reactions to local anaesthetics (LAs) are rare. According 
Table 2 Skin test concentrations for perioperative agents
ENDA European Network for Drug Allergy, SPTs skin prick tests, IDTs Intradermal 
tests








Thiopental 25 2.5 0.2
Propofol 10 1 10–1 10–0.1
Ketamine 10 1 10 0.25
Etomidate 2 0.2 2 0.2–0.002
Midazolam 5 0.5 5 0.5–0.25






Atracurium 1 0.01 10 0.01
Cis-atracurium 2 0.02 2 0.01–0.001
Mivacurium 0.2 0.002
Rocuronium 10 0.05 10 0.01–0.001
Vecuronium 4 0.4 10 0.1–0.001
Pancuronium 2 0.2 2 0.02
Suxamethonium 10 0.1
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to the USpp [9], a SPT with the undiluted anaesthetic and 
a DPT is the reasonable approach. The EUgd [6] recom-
mend using neat LAs for SPTs and a 1/10 dilution for 
IDTs. As cross-reactivity has been reported among ester-
type LAs, but not among amide LAs, in confirmed LA 
allergy, this document [6] also recommends testing other 
LAs in order to identify a safe alternative. For NIDHRs, it 
[6] recommends IDT with a 1/10 dilution of LAs and PTs 
with neat LAs. The USpp on contact dermatitis indicates 
PTs for NIDHRs [13].
Iodinated contrast media, gadolinium chelates and dyes
The USpp [9] does not consider STs a useful tool in 
evaluating hypersensitivity reactions to ICM, argu-
ing that such reactions are non-IgE mediated with rare 
exceptions. Moreover, although it states that the mecha-
nism of NIDHRs to ICM appears to be T-cell mediated, 
as happens with other drugs in the U.S., both PTs and 
delayed-reading STs are not indicated [9]. On the con-
trary, the EUgd recommend STs with a panel of ICM to 
diagnose cross-reactivity and identify safe alternatives. 
In NIDHRs, both delayed-reading IDTs and PTs should 
be carried out to enhance sensitivity; however, false-
negative STs may occur [6]. According to this document 
[6], SPTs with ICM, gadolinium chelates, blue dyes (pat-
ent and methylene), and fluorescein are performed undi-
luted, whereas IDTs with drugs 1/10 diluted (except for 
methylene blue, which is 1/100). PTs are only applied 
with ICM and fluorescein undiluted.
Other drugs
The USpp [9] and EUgd [6] agree that STs are useful for 
evaluating DHRs, such as those to insulin, corticoster-
oids, and heparins. The EUgd [6] highlight the impor-
tance of evaluating NIDHRs to these drugs by using 
PTs and delayed-reading IDTs and provide informa-
tion on non-irritant concentrations for STs with several 
other drugs, such as biological agents (e.g., adalimumab, 
etanercept, infliximab, and omalizumab), proton pump 
inhibitors, H2 antihistamines, antihypertensive drugs 
(i.e., calcium channel blockers and β-blockers), vaccines, 
abacavir, and anticonvulsants.
In vitro tests
The selection of in vitro methods mainly depends on the 
mechanisms involved, IgE- or T-cell-mediated, and their 
availability for a specific drug. Although they have great 
advantages, their value in real life conditions is not clear 
due to the lack of well-controlled studies with a sufficient 
number of confirmed cases. Moreover, evident differ-
ences exist between the American and European points 
of view [4, 30, 31]. The recent ENDA position paper [30] 
concluded that, although many in vitro tests could help in 
diagnosis, few showed at least grade B recommendation 
(Table  3). The National Institute of Allergy and Infec-
tious Diseases (NIAID) Division of Allergy, Immunol-
ogy and Transplantation [31] recommends in vitro tests 
for diagnosing IDHRs when an IgE mechanism is likely 
but STs are neither available nor validated. In an attempt 
to include European and American organizations, the 
ICON (International CONsensus) document [4] indi-
cated the need for new and validated biological diagnos-
tic tests, available to all clinicians, in order to improve 
care for these patients.
Tryptase level
The serum tryptase level can be helpful to confirm a 
diagnosis of anaphylaxis in IDHRs, especially if blood is 
drawn 60–90  min after symptom onset, with on-going 
symptoms, and at least 24  h after resolution. The USpp 
recommends tryptase evaluation in all patients with 
known or suspected anaphylaxis [9].
Specific IgE determination
The detection of drug-sIgE in serum is based on immu-
noassays: radioimmunoassay, enzymoimmunoassay, 
and fluoroimmunoassay (FEIA). The most widely used 
commercial method is the FEIA (ImmunoCAP, Ther-
mofisher, Uppsala, Sweden), although it is only suit-
able for a limited number of drugs, including some 
β-lactams, NMBAs, chlorhexidine, and biological agents. 
Its sensitivity depends on the drug involved, being gen-
erally rather low (0–50%) for β-lactams [32–38], variable 
(44–92%) for NMBAs [39–41], and high for cetuximab 
(68–92%) and chlorhexidine (91.6%) [42–44]. Moreover, 
this test has shown to be concordant and complementary 
with STs [32, 33, 36–41, 44], although with lower sensi-
tivity [9].
The EUgd recommend ImmunoCAP for diagnosing 
IDHRs to β-lactams, NMBAs, chlorhexidine, and bio-
logical agents; in case of severe reactions, it should be 
performed before STs [30]. In the U.S. experience, peni-
cillin is the only low-molecular-weight agent for which 
validated testing has been documented [9], although 
with no concordance with STs and DPTs, indicating no 
apparent usefulness in diagnosing patients with histories 
of penicillin allergy [45]. A lack of specificity has been 
also found in a European report for penicillin V-sIgE 
[46].
Moreover, it is accepted in both European and North 
American guidelines that, although a positive penicillin 
in vitro test in the context of a suggestive history is highly 
predictive of an IgE-mediated allergy, a negative test does 
not rule out an IgE-mediated allergy [9, 30].
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Basophil activation test
There is an increasing interest in the basophil activation 
test (BAT), mainly because it can be used for many drugs. 
This test is based on the flow-cytometric determination 
of basophil activation after stimulation with the drugs or 
their metabolites. Although commercially available, pro-
tocols are not standardized between labs.
In Europe, there are validated studies for β-lactams, 
NMBA, pyrazolones, and fluoroquinolones, showing 
complementarity to STs. For β-lactams, including cla-
vulanic acid, the sensitivity ranges from 22 to 55%, with 
a specificity of 79–96% [35, 47–50]. Regarding NMBAs, 
BAT sensitivity ranges from 64 to 85.7% and specificity 
from 93 to 100%, being especially high for rocuronium 
(91.7%) [41, 51, 52]. The BAT is useful for pyrazolones 
and fluoroquinolones, with a sensitivity of 42–55 [53, 
54] and 36–71% [55, 56] respectively and specificity of 
86–100%. Moreover, for fluoroquinolones, BAT has dem-
onstrated a high NPV, useful for deciding whether to per-
form DPTs [55, 57].
Thus, the EUgd recommend the BAT in high-risk 
patients, when available, and before DPTs and even STs 
[30]. However, the USpp indicates that further confirma-
tory studies are needed since no commercially available 
BAT assay in the U.S. has proven validity [9]. Moreover, 
as with immunoassays, BAT should be performed within 
1 year after healing [54, 58, 59].
More controversy exists about the role of BAT in non-
allergic hypersensitivity to NSAIDs [23] with a great 
variability in sensitivity and specificity among studies 
[60–63]. Importantly, basophil activation by NSAIDs 
occurs to a variable extent in healthy individuals who tol-
erate NSAIDs, decreasing test specificity and NPV. All 
these data have generated a general consensus between 
European and North American guidelines, indicating 
that BAT is not useful for diagnosing non-allergic hyper-
sensitivity to NSAIDs [51, 61–64].
HLA‑allele determination
Different studies have indicated strong associations of 
some HLA alleles with a high risk of severe T-cell medi-
ated reactions to drugs like abacavir, carbamazepine, and 
allopurinol. HLAB*57:01 is associated with DRESS/DiHS 
induced by abacavir in most ethnic populations (sensi-
tivity: 45.5–80%; specificity: 97.6–99%) [65–67]. Moreo-
ver, HLA-B*57:01 screening reduced the prevalence of 
abacavir-induced DHRs from 7.8% in controls to 3.4% 
in screened patients, demonstrating that this genetic 
testing is cost-effective in many countries [65]; however, 
it should be noted that this screening does not prevent 
other types of abacavir DHRs [31].
For carbamazepine, HLA-B*15:02 has been strongly 
associated with SJS/TEN in Asian populations [68–71], 
thus the European Medicines Agency and U.S. Food and 
Drug Administration recommend its screening before 
starting a treatment with this drug in at-risk popula-
tions [72]. HLA-B*58:01 allele is associated with a high 
risk of allopurinol-induced DRESS and SJS/TEN in Asian 
and Caucasian populations [73, 74] and its screening is 
recommended by the American College of Rheumatol-
ogy but not by the U.S. Food and Drug Administration. 
Given the low prevalence of allopurinol hypersensitivity 
and high prevalence of HLA-B*58:01 in Asian patients, 
the usefulness of screening has been questioned [72, 75]. 
Similar recommendations are made in a recent ENDA 
review article [30].
With these data there is a consensus about the need of 
performing genetic testing for specific drugs, although 
their predictive values need to be improved [31].
Lymphocyte transformation test
This test determines the proliferation of drug specific 
T-cells upon stimulation with suspected drug(s). The 
sensitivity and specificity are highly variable, and depend 
on the culprit drug [51, 76]. For β-lactams and anticon-
vulsants the lymphocyte transformation test (LTT) has 
demonstrated fair sensitivity (60–70%) and specificity 
(85–93%) [77]. LTT sensitivity also depends on the type 
of reaction, being quite high in MPE, FDE, AGEP, and 
DRESS, but low in SJS/TEN [51].
The European and North American guidelines [9, 30] 
indicate that although the LTT may be useful as a retro-
spective indicator of cell-mediated DHRs, its PPV and 
NPV have not been determined and it is not available in 
most centres. Thus, to increase its clinical applicability, 
large-scale studies are needed.
Enzyme‑linked immunosorbent spot
Enzyme-linked immunosorbent spot (ELISpot) measures 
cells secreting different mediators upon drug stimulation 
and is useful for evaluating the specific effector response. 
Although recent studies its usefulness, especially in 
severe cases, neither American nor European guidelines 
currently recommend this testing [30, 78–80].
Drug provocation tests
Drug allergy experts worldwide consider the DPT as the 
gold standard for the identification of a culprit drug in 
patients with a suspected DHR. However, the U.S. uses 
different terminology for DPTs, specifically graded chal-
lenges and test doses [9]. Both the European position 
paper [7] and the USpp [9] consider that DPTs are mainly 
intended to exclude a hypersensitivity in non-suggestive 
histories or to provide safe alternatives in allergic patients 
and thus prove tolerance. This is especially true since for 
many drugs there are no standardized STs [6] or in vitro 
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tests [30] nor well established NPV and especially PPV 
of these tests. Only the European document [7] empha-
sizes their role in the establishment of a firm diagnosis of 
DHRs.
Similarities and differences have been previously 
highlighted in the ICON [4]. There are indeed many 
similarities between Europe and the U.S.; however, the 
biggest difference is in the clinical indication of when to 
undertake DPTs. The USpp [9] recommends DPTs only 
if the probability of DHRs is low and the clinical sce-
nario justifies the possible risk, e.g., there is no compa-
rable alternative medication. DPTs are also performed 
for patients with multiple drug allergy syndrome whose 
medical care is impacted by their challenging allergy 
list. It states that the “objective of a graded challenge 
is to introduce a medication cautiously so as not to 
induce a severe reaction” [9]. An exception described 
in the USpp [9] is the possible role of DPTs with aspi-
rin in NSAID-exacerbated respiratory disease (NERD). 
Since there is no ST or in  vitro test for NERD, where 
aspirin desensitization is very effective, if a definitive 
diagnosis is required, DPT is indicated. However, most 
U.S. drug allergy specialists desensitize in most cases 
if there is a highly suspected drug. DPT protocols vary 
and guidelines are only suggestive, not coercive. The 
USpp [9] considers that utilizing more than 4 or 5 steps 
may induce tolerance, whereas European DPT protocols 
often use 4–6 steps.
β-Lactam challenge protocols for NIDHRs vary con-
siderably in the U.S. in terms of initial dosing (e.g., 
graded vs. full dose) and duration of challenge (1 day vs. 
extended several day challenges). In the U.S., Antibiotic 
Stewardship recommends minimizing antibiotic use [12]. 
Thus, most U.S. allergists no longer prescribe multiple 
day provocative challenges to antibiotics in patients who 
do not require antibiotic therapy.
The USpp [9] and European position paper [7] attribute 
different values to negative DPTs (Table  5). This diver-
gence may be due to the different DPT aims (Europe: 
both to exclude and confirm diagnosis of DHRs vs. U.S.: 
mainly to exclude diagnosis of DHRs i.e., low clinical sus-
picion of DHR).
Both documents [7, 9] agree on the precautions, con-
traindications, and surveillance required for DPTs 
(Table  4), although they are generally safe procedures 
[81]. Finally, European and U.S. documents [9, 14, 15] 
mention potential resensitization by DPTs in subjects 
with hypersensitivity reactions to β-lactams (Table 5).
Conclusions
While a general consensus exists on the importance of 
STs for evaluating DHRs, Americans and Europeans 
agree solely on their use for IDHRs (Table 5). Although 
in vitro tests may be helpful, particularly for severe life-
threatening DHRs when STs are negative or not possible 
or contraindicated, they are used almost exclusively in 
Europe. In order to improve drug allergy testing, we must 
standardize protocols, and perform large, multi-site stud-
ies in well-characterized patients diagnosed by STs and/
or DPTs when possible, to confirm drug-specific sensitiv-
ity, specificity, NPV, and PPV. Finally, DPTs are often the 
only reliable way to establish a diagnosis, but this pro-
cedure should be undertaken only in case of a compel-
ling need and with caution. Regarding these matters, the 
position papers from both continents completely agree.
Abbreviations
DHR: drug hypersensitivity reaction; IDHR: immediate 
drug hypersensitivity reaction; NIDHR: non-Immediate 
drug hypersensitivity reaction; SCAR: serious cutane-
ous adverse reaction; AGEP: acute generalized exanthe-
matous pustulosis; TEN: toxic epidermal necrolysis; 
SJS: Stevens–Johnson syndrome; DRESS: drug reaction 
with eosinophilia and systemic symptoms; DiHS: drug-
induced hypersensitivity syndrome; FDE: fixed drug 
eruption; ST: skin test; DPT: drug provocation test; EUgd: 
European guidelines; SPT: skin prick test; IDT: intrader-
mal test; PT: patch test; USpp: US practice parameter; 
Table 4 Precautions and contraindications of performing drug provocation tests (DPTs) (from ICON with permission [4])
DHRs drug hypersensitivity reactions, SJS Stevens–Johnson syndrome, TEN toxic epidermal necrolysis, DRESS drug reaction with eosinophilia and systemic symptoms, 
AGEP acute generalized exanthematous pustulosis
DPTs are contraindicated in non-controllable  
and/or severe life-threatening DHRs
Severe cutaneous reactions, such as SJS, TEN, DRESS, vasculitis, AGEP
Systemic reactions such as DRESS, any internal organ involvement, hema-
tological reactions
Anaphylaxis may be tested after discussion with patient of risk and benefits
DPTs are not indicated The offending drug is unlikely to be needed and several structurally unre-
lated alternatives exist
Severe concurrent illness or pregnancy (unless the drug is essential for the 
concurrent illness or required during pregnancy or delivery)
DPTs should be performed under  
the highest safety conditions
Trained staff that are: familiar with allergy tests, can identify early signs of a 
positive reaction, and can manage life-threatening allergic reactions
Emergency resuscitative equipment should be available
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NPV: negative predictive value; sIgE: specific IgE; ENDA: 
European Network on Drug Allergy; EAACI: European 
Academy of Allergy and Clinical Immunology; ICM: iodi-
nated contrast media; PPL: benzylpencilloyl-poly-l-ly-
sine; MDM: minor determinant mixture; PPV: positive 
predictive value; NSAID: non-steroidal anti-inflamma-
tory drug; SNIUAA: single-NSAID-induced urticaria/
angioedema or anaphylaxis; NMBA: neuromuscular 
blocking agent; LA: local anaesthetic; NIAID: National 
Institute of Allergy and Infectious Diseases; ICON: Inter-
national CONsensus; BAT: basophil activation test; LTT: 
lymphocyte transformation test; ELISpot: enzyme-linked 
immunosorbent spot; FEIA: fluoroimmunoassay; NERD: 
NSAID-exacerbated respiratory disease.
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